Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Endometrial cancer is the most common gynaecological malignancy in women in Europe and the USA. Although most cases are detected at an early stage and cured with surgery alone or with adjuvant therapy, women with advanced or metastatic endometrial cancer have a poor prognosis, and few treatment options are available.